- Email: [email protected]
CME Test Questions: July 2013
CME TEST QUESTIONS: JULY 2013
Examination available at http://learn.sirweb.org/. To take the online JVIR CME tests, please log into the SIR Learning Center with your SIR user name and password. Nonmembers: If you do not already have an SIR username and password, please click on “Create an Account” to gain access to the SIR Learning Center. Once in the Learning Center, click on the “Publication” activity type for a listing of all available JVIR CME Tests. Each test will be available online for 3 years from the month/date of publication. The CME questions in this issue are derived from the article “Survival Outcomes and Prognostic Factors of Transcatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastases” by Hur et al. 1. Neuroendocrine tumors (NETs) most commonly metastasize to: a) The liver b) The spleen c) The axial skeletal system d) The brain 2. In this study, complete or partial response (RECIST) of hepatic metastasis from NETs following transcatheter arterial chemoembolization was observed in: a) o 10% of patients b) 20%–30% of patients c) 40%–70% of patients d) 4 70% of patients 3. In this study, the median overall survival for nonpancreatic NETs following chemoembolization was in the range of: a) 3–6 weeks b) 6–12 months c) 3–5 years d) 5–10 years
4. On a multivariate analysis, the authors concluded that all of the following were significant prognostic factors for overall survival following chemoembolization EXCEPT: a) Total hepatic tumor burden b) Total number of chemoembolizations c) Presence of enterobiliary communication d) Presence of extrahepatic metastasis 5. Following chemoembolization, the presence of an enterobiliary communication puts the patient at a significantly higher risk for: a) Postembolization syndrome b) Encephalopathy c) Variceal hemorrhage d) Liver abscess
Examination available at http://learn.sirweb.org/. To take the online JVIR CME tests, please log into the SIR Learning Center with your SIR user name and password. Nonmembers: If you do not already have an SIR username and password, please click on “Create an Account” to gain access to the SIR Learning Center. Once in the Learning Center, click on the “Publication” activity type for a listing of all available JVIR CME Tests. Each test will be available online for 3 years from the month/date of publication. The CME questions in this issue are derived from the article “Survival Outcomes and Prognostic Factors of Transcatheter Arterial Chemoembolization for Hepatic Neuroendocrine Metastases” by Hur et al. 1. Neuroendocrine tumors (NETs) most commonly metastasize to: a) The liver b) The spleen c) The axial skeletal system d) The brain 2. In this study, complete or partial response (RECIST) of hepatic metastasis from NETs following transcatheter arterial chemoembolization was observed in: a) o 10% of patients b) 20%–30% of patients c) 40%–70% of patients d) 4 70% of patients 3. In this study, the median overall survival for nonpancreatic NETs following chemoembolization was in the range of: a) 3–6 weeks b) 6–12 months c) 3–5 years d) 5–10 years
4. On a multivariate analysis, the authors concluded that all of the following were significant prognostic factors for overall survival following chemoembolization EXCEPT: a) Total hepatic tumor burden b) Total number of chemoembolizations c) Presence of enterobiliary communication d) Presence of extrahepatic metastasis 5. Following chemoembolization, the presence of an enterobiliary communication puts the patient at a significantly higher risk for: a) Postembolization syndrome b) Encephalopathy c) Variceal hemorrhage d) Liver abscess